Alliance Pharma PLC (ISE:APH)

Alliance Pharma PLC (ISE:APH)

Share Price
70.00 p
-0.9 (-1.27 %)
Market Cap
£363.31 m
Proactive Investors - Run By Investors For Investors

Alliance Pharma PLC

Alliance is a publicly owned international pharmaceutical company listed on AIM, part of the London Stock Exchange. We started trading in 1998 and have grown strongly to an annual turnover over £100 million.

At the heart of our business sits a diverse team of dedicated, enthusiastic and experienced professionals who are committed to providing much needed medicines around the...

Market: ISE:APH
52-week High/Low: 102.000p / 59.200p
Sector: Pharma & Biotech
Market Cap: £363.31 m
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Alliance Pharma PLC

Alliance Pharma PLC Snapshot

Vision & Values

Our vision for Alliance Pharma is to breathe life into medicines around the world. We will remain dedicated to patients and continue to serve our shareholders by remaining true to our core values.



Our high performing people continually drive business success.


We set stretching goals and targets we believe are achievable.



We take responsibility and deliver what we promise.


We build trust in all our relationships through openness and fairness.



We recruit highly skilled people and develop their talents to the full.


Our people think of the business as if it was their own.


Our product portfolio has grown and diversified through acquisition over the years.

Across the range, our brands span a wide variety of therapeutic areas. We provide many products to hospitals and pharmacies to fulfil prescriptions and others can be purchased over the counter and in general stores.


Therapy Areas

Our product portfolio covers a wide variety of therapeutic areas. Click on a therapy area for more information about our products.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

See for how to report side effects.


A - Z of Products

If you know the name of the product or brand you are looking for please use our alphabetical list for a quick and easy overview of our product portfolio.



Peter Butterfield, Chief Executive Officer

Peter joined the board of Alliance in February 2010 following the acquisition of Cambridge Laboratories, where he spent five years, latterly as UK Commercial Director. With over 19 years industry experience, he has also served as a Board Member of the Association of the British Pharmaceutical Industry ("ABPI") and played a pivotal role in the 2014 PPRS negotiations with government.. Prior to joining Cambridge Laboratories, Peter spent six years at GlaxoSmithKline. He holds an honours degree in Pharmacology from the University of Edinburgh.


John Dawson, Non-Executive Director

ohn founded Alliance in 1996. He gained multi-disciplinary experience in the pharmaceutical industry over 30 years. John held various senior roles at Sandoz (now Novartis AG) as Director of Finance and Administration and Deputy Managing Director. John has a BSc (Pharmacy) and an MSc (Finance) from the London Business School.


Nigel Clifford, Non-Executive Director

Nigel joined the board of Alliance as a Non-Executive Director on 26 January 2015. He is currently Operating Partner at Marlin Equity Parnters, having been previously Chief Executive at Ordnance Survey and  Procserve Holdings Limited. He is also currently a Non-Executive Director of Anite plc. He has previously held senior positions at Micro Focus International plc, Nokia, Symbian Software Ltd, Tertio Telecoms Limited, Cable and Wireless plc, Glasgow Royal Infirmary NHS Trust and BT plc. Nigel graduated in Geography from the University of Cambridge and has an MBA from Strathclyde University.


David Cook, Chairman

David joined the board of Alliance as a non-executive director in 2014. He is currently Chief Financial Officer and an Executive Director of Ellipses Pharma, an international cancer drug development company, and was previously Chief Financial Officer and Chief Business Officer of Biotie Therapies Corp, a drug development company quoted in Helsinki and on NASDAQ. He has previously held senior financial positions with Jazz Pharmaceuticals International, EUSA Pharma and Zeneus Pharma. David qualified as a chartered accountant with PricewaterhouseCoopers after graduating in chemistry at the University of Oxford.

David has extensive experience of financial and general business management (including the implementation of buy and build strategies) in the life sciences sector, of financing those businesses and managing investor relations across a number of stock markets globally


Andrew Franklin, Chief Financial Officer

Andrew joined the board of Alliance on the 28 September 2015 following his appointment as Chief Financial Officer. From 2010 to 2012, Andrew was Finance Director and Company Secretary of Genzyme Therapeutics Ltd.  Prior to that, he gained 12 years’ pharmaceutical experience with Wyeth in a variety of senior financial positions.  Andrew joins Alliance from Panasonic Europe Ltd, where he was General Manager, European Tax and Accounting. He qualified as a Chartered Accountant with Arthur Andersen in 1992 having graduated with an honours degree in Civil Engineering from the University of Wales, Cardiff in 1988.

Major Shareholders

Shares in Issue: 518,102,971 p Ords
Last updated: 6 December 2018

Major Shareholders Amount % Holding
Directors, Employees & Related Parties 55,787,812 10.77
Fidelity Management & Research 51,512,729 9.94
Slater Investment 41,802,721 8.07
MVM Life Science Partners LLP 37,544,892 7.25
BlackRock Inc 35,175,904 6.79
RIT Capital Partners Plc 18,574,295 3.58
Affiliated Managers Group 17,304,310 3.34


Alliance Pharma plc
Avonbridge House
Bath Road
Wiltshire SN15 2BB
United Kingdom

Telephone +44 [0]1249 466966
Fax +44 [0]1249 466977
Email [email protected]
Email [email protected]

[email protected]

Investor Relations:
[email protected]

Business Development:
[email protected]

[email protected]

[email protected]

Advisers and Registrars

Company Secretary

Chris Chrysanthou

Corporate Advisers

Broker & Nominated Adviser: Numis Securities 
Bank: Lloyds Bank, Royal Bank of Scotland and Silicon Valley Bank
Auditor: KPMG LLP
Financial PR: Buchanan Communications

Registrars Details

The Company's share register is maintained on our behalf by Capita Registrars, who are responsible for updating the register, including changes to shareholders' addresses, purchases and sales of the Company's shares. If you have any questions about your shareholding in Alliance Pharma or need to notify any changes to your personal details please contact them at the following address. 

Capita Asset Services
The Registry
34 Beckenham Road
Kent BR3 4TU

Telephone 0871 664 0300
Lines are open 9:00am - 5:30pm Mon-Fri. Calls cost 10p per minute plus network extras.
Overseas +44 20 8639 3399
Fax +44 (0)20 8639 2220
Email: [email protected]


Contact Us

Whether you are a healthcare professional, prospective employee, investor or customer, you’ll find the right telephone number or email address below. 

Get in Touch

 Alliance Pharma plc

Avonbridge House
Bath Road
Wiltshire SN15 2BB
United Kingdom

Telephone +44 [0]1249 466966

Fax +44 [0]1249 466977

Email [email protected]

Email [email protected]


[email protected]

Investor Relations:
[email protected]
Business Development:
[email protected]
[email protected]
[email protected]


Alliance Pharma plc
Registered Office, Chippenham
Registered in England
Company Number 04241478

Alliance Pharmaceuticals Limited
Registered Office as above
Registered in England
Company Number 03250064


Columns Including APH


Market Reports Including APH

Video RSS



© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use